RHGEN Secures China's First hMPV mRNA Vaccine Clinical Trial Acceptance, Pioneering New Respiratory Vaccine Track

SHENZHEN, China — China's Center for Drug Evaluation (CDE) accepted a clinical trial application on August 7, 2026, for a freeze-dried bivalent human metapneumovirus (hMPV) mRNA vaccine, marking the first such application in the country and positioning Shenzhen-based RHGEN at the forefront of a rapidly evolving respiratory vaccine market.

The application, filed by Wuhan Ruiji Biotechnology—a subsidiary of RHGEN—carries registration number CXSL2600842 and is classified as a Class 1.1 new drug under China's regulatory framework. The vaccine falls under the category of preventive biological products, according to CDE records.

Human metapneumovirus, first identified in 2001 by Dutch researchers in pediatric respiratory samples, has emerged as a significant cause of acute lower respiratory tract infections globally. According to the Global Burden of Disease Study, approximately 14.2 million children under age 5 experience hMPV-related infections annually, with roughly 643,000 requiring hospitalization.

In China, surveillance data from the Chinese Center for Disease Control and Prevention shows hMPV exhibits distinct seasonal patterns, typically peaking during winter and spring months. In 2026, the virus accounted for approximately 5.5% of respiratory pathogen detections nationwide—lower than influenza but significant enough to warrant attention, particularly among children under 5 and adults over 60, who show the highest infection rates.

Despite more than two decades since its discovery, no hMPV vaccine has achieved regulatory approval anywhere in the world. The gap reflects both technical challenges—including difficulties in virus cultivation and complex antigen design—and a historical underestimation of clinical demand, given the virus's relatively mild symptoms compared to other respiratory pathogens.

RHGEN, founded in 2019 and headquartered in Shenzhen with research and production centers in Wuhan and Shanghai, has positioned itself as one of China's few companies with a comprehensive, proprietary mRNA technology platform. The company holds nearly 200 domestic and international patents and has built its competitive moat around three core technologies: the Rh-Cosmo AI design platform, a proprietary cationic lipid T19 delivery system, and mRNA-LNP freeze-dried formulation technology.

CEO Hu Yong, who brings nearly a decade of mRNA research experience to the role, has led the company in developing a multi-indication pipeline that spans respiratory viruses, shingles, and tuberculosis. The company's RSV mRNA vaccine received CDE clinical approval in March 2025 and is currently in Phase I trials. A freeze-dried shingles mRNA vaccine has also secured regulatory approval, while its tuberculosis candidate, RH119, is advancing through clinical research.

The freeze-dried formulation represents a critical differentiator for RHGEN's approach. Traditional mRNA vaccines require ultra-cold storage at temperatures ranging from -20°C to -70°C, creating significant logistical barriers, particularly in rural and resource-limited settings. RHGEN's technology enables storage at standard refrigeration temperatures of 2-8°C while maintaining mRNA stability and biological activity—a capability the company has applied across multiple pipeline candidates.

The practical implications are substantial. Refrigerated storage dramatically reduces cold chain costs, extends product shelf life, improves vaccine accessibility in primary healthcare settings, and facilitates the development of combination vaccines that target multiple pathogens in a single dose.

Additionally, RHGEN's proprietary cap analog structure, RHCap2-6, has completed Drug Master File registration with the U.S. Food and Drug Administration—a regulatory milestone that enhances the immunogenicity and stability of the company's mRNA products and applies to the hMPV vaccine candidate among others.

Globally, the hMPV vaccine race remains in early stages. Moderna developed mRNA-1653, a combination vaccine targeting hMPV and parainfluenza virus type 3, which completed Phase I and Ib trials with favorable safety and immunogenicity data but has seen slower subsequent progress. Sanofi Pasteur has initiated Phase I testing of a triple-combination RSV-HMPV-HPIV3 mRNA vaccine for adults over 60, while Invivyd's IVX-A12—a bispecific antibody therapeutic rather than a preventive vaccine—has advanced to Phase III for hMPV indications.

The development challenges are notable. hMPV's F protein, the primary antigen target, presents greater stability challenges in its prefusion conformation compared to similar proteins in other respiratory viruses. Combined with the virus's difficulty in cell culture and historically modest clinical attention, these factors have contributed to a development timeline that lags behind the recent breakthroughs seen in RSV vaccines.

Within China, the competitive landscape for hMPV vaccines remains nascent. Kangtai Biological has a combination RSV-hMPV vaccine in preclinical development, while Yuekang Pharmaceutical is exploring hMPV as a potential expansion of its mRNA platform. RHGEN's first-mover advantage in clinical applications positions it favorably, though the long development timelines and inherent uncertainties of vaccine research mean the ultimate market leader remains undetermined.

The larger commercial opportunity may lie in combination vaccines. Respiratory viruses including RSV, influenza, and hMPV exhibit highly overlapping seasonal patterns, creating natural demand for multi-pathogen formulations that improve vaccination efficiency and patient compliance. RHGEN's parallel development of RSV and hMPV candidates—its RSV vaccine already approved for investigational new drug status—positions the company to potentially develop bivalent or multivalent combination products with inherent advantages.

The mRNA technology platform, which gained prominence during the COVID-19 pandemic, is increasingly expanding from emergency vaccine applications into conventional vaccine markets. RSV, hMPV, shingles, tuberculosis—traditional vaccine categories are being redefined by mRNA innovation, and RHGEN's hMPV application represents both a new indication exploration for Chinese mRNA vaccine companies and a broader reflection of China's vaccine industry transformation toward innovation-driven development.

Clinical trial acceptance, however, represents only the beginning of a lengthy regulatory journey. Phase I, II, and III trials lie ahead, each presenting potential hurdles related to safety, efficacy, manufacturing processes, and quality control. The critical question is not who files first, but which company can deliver robust clinical data, establish genuine differentiation through freeze-drying technology and combination vaccine strategies, and ultimately translate laboratory breakthroughs into products that reach patients.

The global hMPV vaccine competition has just begun. Chinese companies have reached the starting line.